Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Prospective Randomized Trial Protocol for Duration of Post-Operative Tazocin Treatment After Whipple Operation

9. november 2026 oppdatert av: Tel-Aviv Sourasky Medical Center

Pancreaticoduodenectomy (Whipple procedure) is associated with substantial postoperative morbidity, mainly infectious complications and postoperative pancreatic fistula. Perioperative antibiotic prophylaxis is routine, but the optimal strategy for postoperative antibiotic administration is unclear, and practice varies between surgeons.

The objective of this study is to determine whether the duration of postoperative piperacillin-tazobactam (24 hours versus 5 days) affects postoperative infectious outcomes in patients undergoing pancreaticoduodenectomy.

This is a single-center, prospective, randomized clinical trial in adults undergoing open or minimally invasive (robotic) pancreaticoduodenectomy. All consented patients receive perioperative piperacillin-tazobactam according to institutional practice. After the operation is completed, patients who underwent pancreaticoduodenectomy and remain eligible are randomized by a computerized system, stratified by presence of a preoperative biliary stent and by surgical approach, to postoperative antibiotic treatment for 24 hours or 5 days.

The primary endpoint is the rate of postoperative infectious complications, comprising superficial wound infection, deep (fascial) surgical site infection, and intra-abdominal infection, defined according to CDC criteria, [within 30 days after surgery]. Participation does not change surgical technique, length of hospitalization, or routine follow-up.

As an exploratory component, intraoperative bile cultures are collected to describe biliary microbial profiles and antibiotic resistance patterns.

The study aims to provide high-quality evidence to guide postoperative antibiotic management and support more rational use of broad-spectrum antibiotics in pancreatic surgery.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

BACKGROUND AND RATIONALE

Pancreaticoduodenectomy (Whipple procedure) is a standard surgical treatment for benign and malignant diseases of the pancreatic head and periampullary region. The operation carries high morbidity and mortality. The most common complications are postoperative infections and pancreatic fistula, occurring in approximately 30-50% of patients. These complications reduce quality of life, limit the ability to complete adjuvant chemotherapy, and are associated with lower overall survival.

Biliary infection, particularly after preoperative biliary stenting, is a major contributor to postoperative infections. Stenting alters the biliary microbial profile and often leads to colonization with organisms associated with higher rates of postoperative infection and pancreatic fistula. These organisms frequently show resistance to standard prophylactic antibiotics, which highlights the importance of matching antibiotic regimens to the patient's microbial profile.

Perioperative antibiotic prophylaxis is routinely administered during pancreatic surgery. However, continuation of antibiotics after surgery varies between clinicians and is left to the surgeon's discretion, without a defined protocol. Recent studies indicate that broad-spectrum antibiotics such as piperacillin-tazobactam (Tazocin) are superior to cephalosporins in reducing infections after Whipple surgery, particularly in patients with a preoperative biliary stent. However, the optimal duration of therapy remains unclear. Longer treatment may further reduce infections in high-risk populations, but raises concerns regarding antimicrobial resistance, adverse effects, and cost.

OBJECTIVE

To compare the efficacy of short-course (24 hours) versus extended (5 days) postoperative piperacillin-tazobactam in reducing infections after pancreaticoduodenectomy. By optimizing antibiotic duration, the study seeks to balance infection prevention and clinical outcomes against responsible antibiotic stewardship, and to propose a new standard for managing patients undergoing this operation.

STUDY DESIGN

Single-center, prospective, randomized, open-label clinical trial. A total of 200 participants will be enrolled at Tel Aviv Sourasky Medical Center, undergoing pancreaticoduodenectomy by an open or minimally invasive (robotic) approach.

Written informed consent is obtained before surgery. All participants receive piperacillin-tazobactam before skin incision and during surgery. After the operation is completed, patients in whom pancreaticoduodenectomy was successfully completed and who remain eligible are randomly assigned, using a computerized system, to one of two groups. Randomization is stratified by:

  • Presence or absence of a preoperative biliary stent
  • Surgical approach (open versus minimally invasive/robotic)

These factors were selected because of their potential impact on postoperative infectious risk. Patients in whom pancreaticoduodenectomy is not performed are not randomized and are not included in the study.

  • Group 1: piperacillin-tazobactam for 5 days after the end of surgery
  • Group 2: piperacillin-tazobactam for 24 hours after the end of surgery

Because the antibiotic is ordered as a visible medical order and given intravenously during hospitalization, participants and investigators are aware of group allocation. Participation does not prolong the operation or the usual hospital stay.

PARTICIPANT SELECTION AND CONSENT

Eligible adults scheduled for Whipple surgery are approached in the preoperative clinic or during admission before surgery. Written informed consent is obtained after a full face-to-face explanation, with time for questions, using a digital consent process, or a paper form if the patient declines digital signing or technical problems occur.

Inclusion criteria:

  • Age 18 years or older
  • Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
  • Ability to provide informed consent
  • Completion of pancreaticoduodenectomy, confirmed at the end of the operation

Exclusion criteria:

  • Age under 18 years, pregnancy, or lack of decision-making capacity
  • Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
  • Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles

Removal from the study (before or after randomization):

  • Preoperative microbiological findings requiring an antibiotic regimen other than piperacillin-tazobactam
  • Deviation from the pre-agreed antibiotic protocol or from the recommended postoperative algorithm
  • Reoperation (surgical revision)

INTERVENTION AND DOSING

Intraoperative: piperacillin-tazobactam 4.5 g within 60 minutes before incision, with additional doses every 2-4 hours until the end of surgery, adjusted for renal function.

Postoperative: 4.5 g three times daily, or a reduced dose according to renal function, for 5 days (Group 1) or 24 hours (Group 2).

POSTOPERATIVE CARE AND FOLLOW-UP

Inpatient follow-up is the routine for Whipple surgery: daily physician rounds with history, vital signs, physical examination, drain output, and review of laboratory tests and imaging. Blood tests are routine on postoperative days 1 and 2, and thereafter at the discretion of the treating team. Decisions on CT imaging and on additional antibiotic treatment, regardless of study group, follow the algorithm-based care of the Dutch Pancreatic Cancer Group, agreed in advance by all pancreatic surgeons.

After discharge, participants are followed in the surgical clinic at 1, 3, 6, and 12 months after surgery, and annually thereafter.

OUTCOME MEASURES

Primary endpoint: rate of surgical site infection (SSI) within 30 days of surgery, comprising superficial incisional, deep incisional, and organ/space SSI according to CDC definitions.

Secondary endpoints:

  1. Overall postoperative complication rate
  2. Postoperative pancreatic fistula
  3. Microbial profile and antibiotic resistance at surgery (bile) and afterward
  4. Antibiotic-related adverse events and complications (e.g., Clostridioides difficile infection)
  5. Need for invasive intervention after surgery
  6. Need for reoperation
  7. Overall survival

DATA COLLECTION

Data are collected in coded form, with the coding key held separately by the principal investigator, and are not shared outside the hospital. Collected data include demographics; preoperative clinical variables (BMI, comorbidities, ASA score, biliary stent or drainage, neoadjuvant therapy, pathology); operative variables (approach, duration, pancreatic texture, duct size, blood loss, vascular reconstruction, bile culture results); postoperative course (length of stay, infections, pancreatic fistula grade, C. difficile infection, imaging, interventions, reoperation, other infectious and non-infectious complications); and follow-up to one year (late complications, cancer recurrence, date of last visit or death).

STATISTICAL ANALYSIS

Overall infection rate, infection rate by subtype, and pancreatic fistula rate are compared between the groups using the chi-square test. The same test is used for reoperation, invasive intervention, other postoperative complications, and C. difficile infection. Common bacteria and antibiotic sensitivity profiles are described. Cancer recurrence and overall survival are compared using Kaplan-Meier curves.

STUDY SIGNIFICANCE

This trial compares two durations of postoperative piperacillin-tazobactam in a standardized, randomized setting. The results are expected to guide postoperative antibiotic management, reduce infectious morbidity after pancreaticoduodenectomy, and support more rational use of broad-spectrum antibiotics.

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Rekruttering
        • Department of Hepatobiliary Surgery, Tel Aviv Sourasky Medical Center Tel Aviv, Israel
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
  • Ability to provide informed consent
  • Completion of pancreaticoduodenectomy, confirmed at the end of the operation

Exclusion Criteria:

  • Age under 18 years, pregnancy, or lack of decision-making capacity
  • Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
  • Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Piperacillin-tazobactam for 5 days

Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 5 days after the end of surgery, in addition to perioperative dosing before incision and during surgery.

Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.

Andre navn:
  • Zosyn
  • Tazocin
Eksperimentell: Piperacillin-tazobactam for 24 hours

Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 24 hours after the end of surgery, in addition to perioperative dosing before incision and during surgery.

Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.

Andre navn:
  • Zosyn
  • Tazocin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of surgical site infection (SSI) after pancreaticoduodenectomy
Tidsramme: Within 30 days after surgery

Proportion of participants with surgical site infection, comprising superficial incisional SSI, deep incisional SSI, and organ/space SSI (intra-abdominal infection), as defined by the CDC National Healthcare Safety Network criteria.

Within 30 days after surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall early postoperative complication rate
Tidsramme: Within 30 days after surgery

roportion of participants with any postoperative complication, including pancreatic fistula, infectious complications other than surgical site infection (urinary tract infection, pneumonia, line sepsis), hemorrhage (requiring transfusion or intervention such as angiography), delayed gastric emptying, ileus or early small bowel obstruction, chyle leak, acute kidney injury, venous thromboembolism, and acute coronary syndrome (STEMI/non-STEMI).

Within 30 days after surgery
Postoperative pancreatic fistula
Tidsramme: Within 30 days after surgery

Proportion of participants who develop a postoperative pancreatic fistula, graded A, B, or C according to the International Study Group on Pancreatic Fistula (ISGPS) definition.

Within 30 days after surgery
Late postoperative complications
Tidsramme: Between 30 days and 1 year after surgery

Proportion of participants with complications occurring after the early postoperative period (beyond 30 days), including: anastomotic stricture (biliary, pancreatic-enteric, or gastro/duodeno-enteric); anastomotic or marginal ulcer; late hemorrhage or pseudoaneurysm; delayed intra-abdominal collection or abscess; delayed or recurrent cholangitis; incisional hernia; small bowel obstruction or internal hernia; exocrine pancreatic insufficiency requiring enzyme replacement; new-onset or worsening diabetes mellitus; chronic diarrhea, malabsorption, or weight loss; portal or mesenteric vein thrombosis.

Between 30 days and 1 year after surgery
Need for invasive intervention after surgery
Tidsramme: Within 30 days after surgery

Proportion of participants who require an invasive intervention after the operation (for example, percutaneous drainage or an angiographic procedure), excluding return to the operating room.

Within 30 days after surgery
Early reoperation
Tidsramme: Within 30 days after surgery

Proportion of participants who require a return to the operating room for surgical revision or reintervention after the index operation, for any cause related to the index operation, during the early postoperative period.

Within 30 days after surgery
Late reoperation
Tidsramme: Between 30 days and 1 year after surgery

Proportion of participants who require a return to the operating room for surgical revision or reintervention after the early postoperative period (beyond 30 days), for any cause related to the index operation.

Between 30 days and 1 year after surgery
Antibiotic-related adverse events, including Clostridioides difficile infection
Tidsramme: Within 60 days after surgery

Proportion of participants with adverse events and complications attributable to antibiotic administration, including Clostridioides difficile infection (CDT).

Within 60 days after surgery
Microbial profile and antibiotic resistance
Tidsramme: At surgery (bile cultures) and up to 60 days after surgery

Organisms isolated and their antibiotic susceptibility and resistance profiles, from intraoperative bile cultures and from postoperative blood or other body fluid cultures taken when clinically indicated. Compared between participants with and without a preoperative biliary stent and between study groups.

At surgery (bile cultures) and up to 60 days after surgery
Overall survival
Tidsramme: Up to 5 years after surgery

Time from the date of surgery to death from any cause. Participants alive at last follow-up are censored at the date of last visit. Compared between study groups using Kaplan-Meier curves.

Up to 5 years after surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. mars 2025

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2029

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • TASMC-25-NL-047-CTIL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .